This means reported events may vary depending on the trial dose group and escalation design
2 There are six FDA-approved GLP-1 RAs on the market, including several that are widely recognized in the popular media: exenatide (Byetta, Bydureon)
Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY
Non-semaglutide GLP-1 medications from Henry Meds Henry offers two other GLP-1 RAs in addition to semaglutide: Tirzepatide: the active ingredient in Mounjaro and Zepbound Liraglutide: the active ingredient in Saxenda and Victoza Of the three drugs, tirzepatide has shown the highest weight loss rates in studies, with one study showing nearly 18% of body weight lost after 72 weeks
A 52-week treatment with tirzepatide (5mg, 10mg, or 15 mg) led to a significant MASH resolution without worsening liver fibrosis compared to placebo (Fig.3)
Whats also interesting is how important lifestyle factors were in noting benefits: Smokers, drinkers and those with a higher BMI saw stronger lipid-lowering effects